Hirakawa et al. (2019) evaluated two Wnt/β-catenin signaling inhibitors, ICG-001 and C-82, on the progression of endometriosis. The results suggested that inhibiting the CREB-binding protein (CBP)/β-catenin signal can be a therapeutic target for endometriosis. In another study, Itaba et al. (2019) reported the potent anti-fibrotic therapeutic effect of IC-2, a derivative of ICG-001, on established liver fibrosis. Here, CREBBP is linked to endometriosis.